Univariate Cox analysis of PFS or OS by the levels of circulating cytokines in NSCLC patients who received immunotherapy showed that pretreatment circulating cytokine CXCL12 levels predicted the outcomes of immunotherapy (Table 2). This evidence concerns the gene CXCL12 and non-small cell lung carcinoma.